Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Eupraxia posts DDW positive EP-104GI signals; cash runway supports 2028 milestones

Aug 11, 2026, 5:23 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive DDW data and portfolio advancement combined with a strengthened leadership team can improve valuation optics and reduce execution risk, though net losses and small-sample data cap upside stability.

AI summary

What happened, with direct paths to the underlying reporting

Eupraxia Pharmaceuticals reported Q2 2026 losses but disclosed encouraging DDW data for EP-104GI, including fibrosis and inflammation improvements after a single administration. The company also announced leadership and board enhancements to accelerate late-stage development and global commercialization, with a cash runway to late-2028. The key near-term catalyst is Q4 interim data from the Phase 2b EoE program, which could precede Phase 3 initiation in 2027.

DDW data shows fibrosis and inflammation improvement after a single EP-104GI dose.
Executive team and board strengthened to support late-stage development and commercialization.
Q2 2026 net loss $14.5M; cash $52.4M and investments $81.2M; runway into 2H2028.
RESOLVE trial: Cohort 9 shows 66% symptom remission at week 36; tissue health improves.
Phase 2b EoE interim data expected in Q4; Phase 3 initiation and 2027 GI portfolio expansion.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.